Education
About Us
Working with TipRanks
Follow Us
Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
Total Valuation
Bright Minds Biosciences has a market cap or net worth of C$654.82M. The enterprise value is $204.27M.
Market CapC$654.82M
Enterprise Value$204.27M
Share Statistics
Bright Minds Biosciences has 7,785,761 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,785,761
Owned by Insiders14.17%
Owned by Institutions46.21%
Financial Efficiency
Bright Minds Biosciences’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -49.07%.
Return on Equity (ROE)-0.51
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-49.07%
Return on Capital Employed (ROCE)-0.50
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bright Minds Biosciences is ―. Bright Minds Biosciences’s PEG ratio is 0.03.
PE Ratio―
PS Ratio0.00
PB Ratio1.14
Price to Fair Value1.14
Price to FCF-3.42
Price to Operating Cash Flow-76.80
PEG Ratio0.03
Income Statement
In the last 12 months, Bright Minds Biosciences had revenue of 0.00 and earned -2.80M in profits. Earnings per share was -0.65.
Revenue0.00
Gross Profit-73.36K
Operating Income-2.81M
Pretax Income-2.80M
Net Income-2.80M
EBITDA-2.72M
Earnings Per Share (EPS)-0.65
Cash Flow
In the last 12 months, operating cash flow was -7.89M and capital expenditures -5.00, giving a free cash flow of -7.89M billion.
Operating Cash Flow-7.89M
Free Cash Flow-7.89M
Free Cash Flow per Share-1.01
Dividends & Yields
Bright Minds Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta4.51
52-Week Price Change120.69%
50-Day Moving Average63.98
200-Day Moving Average42.24
Relative Strength Index (RSI)70.50
Average Volume (3m)102.09K
Important Dates
Bright Minds Biosciences upcoming earnings date is Dec 18, 2025, Before Open (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateDec 18, 2025
Ex-Dividend Date―
Financial Position
Bright Minds Biosciences as a current ratio of 11.32, with Debt / Equity ratio of 0.27%
Current Ratio11.32
Quick Ratio11.32
Debt to Market Cap0.01
Net Debt to EBITDA2.06
Interest Coverage Ratio-314.57
Taxes
In the past 12 months, Bright Minds Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bright Minds Biosciences EV to EBITDA ratio is -0.27, with an EV/FCF ratio of -0.40.
EV to Sales0.00
EV to EBITDA-0.27
EV to Free Cash Flow-0.40
EV to Operating Cash Flow-0.40
Balance Sheet
Bright Minds Biosciences has C$51.39M in cash and marketable securities with C$141.03K in debt, giving a net cash position of C$51.25M billion.
Cash & Marketable SecuritiesC$51.39M
Total DebtC$141.03K
Net CashC$51.25M
Net Cash Per ShareC$6.58
Tangible Book Value Per ShareC$1.28
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bright Minds Biosciences is C$89.65, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$89.65
Price Target Upside4.65% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―